Journal article
Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2
Abstract
We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration. Etoricoxib selectively inhibited COX-2 in human whole blood assays in vitro, with an …
Authors
Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret J-P; Friesen RW; Gordon R; Greig G
Journal
Journal of Pharmacology and Experimental Therapeutics, Vol. 296, No. 2, pp. 558–566
Publisher
Elsevier
Publication Date
February 2001
DOI
10.1016/s0022-3565(24)38776-2
ISSN
0022-3565
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AlgorithmsAnimalsAnti-Inflammatory AgentsArachidonic AcidCHO CellsCricetinaeCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsEtoricoxibGastrointestinal DiseasesHumansIonophoresIsoenzymesMaleMembrane ProteinsMicrosomes, LiverProstaglandin-Endoperoxide SynthasesPyridinesRatsRats, Sprague-DawleyRecombinant ProteinsSubstrate SpecificitySulfonesThromboxane B2